BPC-157: what does the evidence actually show?
BPC-157 has broad preclinical research interest, but the human evidence question remains unresolved. Here is what the evidence actually shows.
Read Article →Insights, guides, and articles on peptide research, analytical methods, and best practices.
BPC-157 has broad preclinical research interest, but the human evidence question remains unresolved. Here is what the evidence actually shows.
Read Article →
New research identifies MG53 (TRIM72) as a key regulator of muscle stem cell activation in ageing, and a promising therapeutic…
Read Article →
25+ scientists published a coordinated expert review in Nature Aging confirming NAD+ as a central target in aging research. Here's…
Read Article →
VITAL-H is a $38 million federally funded trial testing rapamycin, semaglutide, and dapagliflozin in 700–1,000 healthy adults aged 60–65. Here’s…
Read Article →
Thymalin, Pinealon, and Vilon are ultra-short bioregulator peptides developed over 40 years by Vladimir Khavinson. Here's what the clinical data…
Read Article →
GHK-Cu is one of the most-studied peptides in existence. Here’s what five decades of research actually shows — mechanism, findings,…
Read Article →
For laboratory and research use only. The Atlantic published a feature today on the underground peptide market — part of…
Read Article →
For laboratory and research use only. Introduction Cellular senescence is one of the more active areas in ageing biology right…
Read Article →
On September 19, 2025, a four-amino-acid peptide became the first approved drug to directly target the inside of a mitochondrion.…
Read Article →